ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 1 filers reported holding ASCENDIS PHARMA A/S in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,559,761 | +3.1% | 16,657 | -1.7% | 2.01% | +10.5% |
| Q2 2023 | $1,512,520 | +32.4% | 16,947 | +59.1% | 1.82% | +15.1% |
| Q1 2023 | $1,142,107 | -58.2% | 10,652 | -52.3% | 1.58% | -39.6% |
| Q4 2022 | $2,729,239 | -9.3% | 22,347 | -23.3% | 2.62% | -9.5% |
| Q3 2022 | $3,010,000 | +42.9% | 29,146 | +28.6% | 2.90% | +26.3% |
| Q2 2022 | $2,106,000 | -52.1% | 22,659 | -39.6% | 2.29% | -25.0% |
| Q1 2022 | $4,401,000 | -23.4% | 37,501 | -12.2% | 3.06% | +10.9% |
| Q4 2021 | $5,746,000 | +55.1% | 42,712 | +83.8% | 2.76% | +67.8% |
| Q3 2021 | $3,705,000 | +62.1% | 23,242 | +33.8% | 1.64% | +56.0% |
| Q2 2021 | $2,285,000 | +5.7% | 17,370 | +3.6% | 1.05% | -17.5% |
| Q1 2021 | $2,161,000 | +6.1% | 16,764 | +37.3% | 1.28% | -17.7% |
| Q4 2020 | $2,037,000 | – | 12,212 | – | 1.55% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |